Juvenile Xanthogranuloma and Nevus Anemicus in the Diagnosis of Neurofibromatosis Type 1 | Congenital Defects | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.173.234.169. Please contact the publisher to request reinstatement.
1.
National Institutes of Health Consensus Development Conference.  Neurofibromatosis: conference statement.  Arch Neurol. 1988;45(5):575-578.PubMedGoogle ScholarCrossref
2.
DeBella  K, Poskitt  K, Szudek  J, Friedman  JM.  Use of “unidentified bright objects” on MRI for diagnosis of neurofibromatosis 1 in children.  Neurology. 2000;54(8):1646-1651.PubMedGoogle ScholarCrossref
3.
Lopes Ferraz Filho  JR, Munis  MP, Soares Souza  A, Sanches  RA, Goloni-Bertollo  EM, Pavarino-Bertelli  EC.  Unidentified bright objects on brain MRI in children as a diagnostic criterion for neurofibromatosis type 1.  Pediatr Radiol. 2008;38(3):305-310.PubMedGoogle ScholarCrossref
4.
Curless  RG, Siatkowski  M, Glaser  JS, Shatz  NJ.  MRI diagnosis of NF-1 in children without café-au-lait skin lesions.  Pediatr Neurol. 1998;18(3):269-271.PubMedGoogle ScholarCrossref
5.
DeBella  K, Szudek  J, Friedman  JM.  Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children.  Pediatrics. 2000;105(3, pt 1):608-614.PubMedGoogle ScholarCrossref
6.
Obringer  AC, Meadows  AT, Zackai  EH.  The diagnosis of neurofibromatosis-1 in the child under the age of 6 years.  Am J Dis Child. 1989;143(6):717-719.PubMedGoogle Scholar
7.
Whitehouse  D.  Diagnostic value of the café-au-lait spot in children.  Arch Dis Child. 1966;41(217):316-319.PubMedGoogle ScholarCrossref
8.
Nunley  KS, Gao  F, Albers  AC, Bayliss  SJ, Gutmann  DH.  Predictive value of café au lait macules at initial consultation in the diagnosis of neurofibromatosis type 1.  Arch Dermatol. 2009;145(8):883-887.PubMedGoogle ScholarCrossref
9.
Landau  M, Krafchik  BR.  The diagnostic value of café-au-lait macules.  J Am Acad Dermatol. 1999;40(6, pt 1):877-890-892.PubMedGoogle ScholarCrossref
10.
Adamson  N.  Congenital xanthoma multiplex in a child.  Br J Dermatol. 1905;17:222-223.Google Scholar
11.
Kupfer-Bessaguet  I, Staroz  F, Plantin  P; la Société Française de Dermatologie Pédiatrique.  Xanthogranulome juvénile.  Ann Dermatol Venereol. 2009;136(1):70-73.PubMedGoogle ScholarCrossref
12.
Lamb  JH, Lain  ES.  Nevoxantho endothelioma: its relationship to juvenile xanthoma.  South Med J. 1937;30:585-594.Google ScholarCrossref
13.
Nomland  R.  Nevoxanthro-endothelioma; a benign xanthromatous disease of infants and children.  J Invest Dermatol. 1954;22(3):207-215.PubMedGoogle ScholarCrossref
14.
Marten  R.  Naevoxanthoendothelioma with pigmentary abnormalities.  Br J Dermatol. 1960;72:308.Google ScholarCrossref
15.
Jensen  NE, Sabharwal  S, Walker  AE.  Naevoxanthoendothelioma and neurofibromatosis.  Br J Dermatol. 1971;85(4):326-330.PubMedGoogle ScholarCrossref
16.
Sourreil  P, Beylot  C, Bioulac  P.  Xanthogranulome juvénile associé à la maladie de Recklinhausen: a propos de 3 cas.  J Med Lyon. 1972;53(232):1165-1171.PubMedGoogle Scholar
17.
Newell  GB, Stone  OJ, Mullins  JF.  Juvenile xanthogranuloma and neurofibromatosis.  Arch Dermatol. 1973;107(2):262.PubMedGoogle ScholarCrossref
18.
Smitt  JH.  Juvenile xanthogranuloma in neurofibromatosis type I.  Br J Dermatol. 1991;125(4):390.PubMedGoogle ScholarCrossref
19.
Ackerman  CD, Cohen  BA.  Juvenile xanthogranuloma and neurofibromatosis.  Pediatr Dermatol. 1991;8(4):339-340.PubMedGoogle ScholarCrossref
20.
Tan  HH, Tay  YK.  Juvenile xanthogranuloma and neurofibromatosis 1.  Dermatology. 1998;197(1):43-44.PubMedGoogle ScholarCrossref
21.
Dehen  L, Zeller  J, Cosnes  A, Bernaudin  F, Roujeau  JC, Revuz  J.  Xanthogranulomes, neurofibromatose de type 1 et leucémie myélomonocytaire spontanément résolutive.  Ann Dermatol Venereol. 1990;117(11):812-814.PubMedGoogle Scholar
22.
Morier  P, Mérot  Y, Paccaud  D, Beck  D, Frenk  E.  Juvenile chronic granulocytic leukemia, juvenile xanthogranulomas, and neurofibromatosis: case report and review of the literature.  J Am Acad Dermatol. 1990;22(5, pt 2):962-965.PubMedGoogle ScholarCrossref
23.
Song  M, Gheeraert  P, Jonckheer  T, Otten  J, Achten  G.  Xanthomes, neurofibromatose et leucémie chez l’enfant.  Dermatologica. 1984;168(3):138-140.PubMedGoogle ScholarCrossref
24.
Raygada  M, Arthur  DC, Wayne  AS, Rennert  OM, Toretsky  JA, Stratakis  CA.  Juvenile xanthogranuloma in a child with previously unsuspected neurofibromatosis type 1 and juvenile myelomonocytic leukemia.  Pediatr Blood Cancer. 2010;54(1):173-175.PubMedGoogle ScholarCrossref
25.
Gutmann  DH, Gurney  JG, Shannon  KM.  Juvenile xanthogranuloma, neurofibromatosis 1, and juvenile chronic myeloid leukemia.  Arch Dermatol. 1996;132(11):1390-1391.PubMedGoogle ScholarCrossref
26.
Benessahraoui  M, Aubin  F, Paratte  F, Plouvier  E, Humbert  P.  Leucémie myélomonocytaire juvénile, xanthomes et neurofibromatose de type 1.  Arch Pediatr. 2003;10(10):891-894.PubMedGoogle ScholarCrossref
27.
Shin  HT, Harris  MB, Orlow  SJ.  Juvenile myelomonocytic leukemia presenting with features of hemophagocytic lymphohistiocytosis in association with neurofibromatosis and juvenile xanthogranulomas.  J Pediatr Hematol Oncol. 2004;26(9):591-595.PubMedGoogle ScholarCrossref
28.
Burgdorf  WHC, Zelger  B.  JXG, NF1, and JMML: alphabet soup or a clinical issue?  Pediatr Dermatol. 2004;21(2):174-176.PubMedGoogle ScholarCrossref
29.
Zvulunov  A, Barak  Y, Metzker  A.  Juvenile xanthogranuloma, neurofibromatosis, and juvenile chronic myelogenous leukemia: world statistical analysis.  Arch Dermatol. 1995;131(8):904-908.PubMedGoogle ScholarCrossref
30.
Huson  SM, Harper  PS, Compston  DA.  Von Recklinghausen neurofibromatosis: a clinical and population study in south-east Wales.  Brain. 1988;111(pt 6):1355-1381.PubMedGoogle ScholarCrossref
31.
Cambiaghi  S, Restano  L, Caputo  R.  Juvenile xanthogranuloma associated with neurofibromatosis 1: 14 patients without evidence of hematologic malignancies.  Pediatr Dermatol. 2004;21(2):97-101.PubMedGoogle ScholarCrossref
32.
Vörner  H.  Über naevus anaemicus.  Arch Derm Syphilol. 1906;82:391-398.Google Scholar
33.
Ahkami  RN, Schwartz  RA.  Nevus anemicus.  Dermatology. 1999;198(4):327-329.PubMedGoogle ScholarCrossref
34.
Butterworth  T, Walters  JD.  Observations on the pharmacologic responses of Voerner’s nevus anemicus.  AMA Arch Derm Syphilol. 1952;66(3):333-339.PubMedGoogle ScholarCrossref
35.
Daniel  RH, Hubler  WR, Wolf  JE, Holder  WR.  Nevus anemicus: donor-dominant defect.  Arch Dermatol. 1977;113(1):53-56.PubMedGoogle ScholarCrossref
36.
Fleisher  TL, Zeligman  I.  Nevus anemicus.  Arch Dermatol. 1969;100(6):750-755.PubMedGoogle ScholarCrossref
37.
Greaves  MW, Birkett  D, Johnson  C.  Nevus anemicus: a unique catecholamine-dependent nevus.  Arch Dermatol. 1970;102(2):172-176.PubMedGoogle ScholarCrossref
38.
Kim  SK, Kang  HY, Lee  E-S, Kim  YC.  Clinical and histopathologic characteristics of nevus depigmentosus.  J Am Acad Dermatol. 2006;55(3):423-428.PubMedGoogle ScholarCrossref
39.
Mountcastle  EA, Diestelmeier  MR, Lupton  GP.  Nevus anemicus.  J Am Acad Dermatol. 1986;14(4):628-632.PubMedGoogle ScholarCrossref
40.
Katugampola  GA, Lanigan  SW.  The clinical spectrum of naevus anaemicus and its association with port wine stains: report of 15 cases and a review of the literature.  Br J Dermatol. 1996;134(2):292-295.PubMedGoogle ScholarCrossref
41.
Happle  R, Koopman  R, Mier  PD.  Hypothesis: vascular twin naevi and somatic recombination in man.  Lancet. 1990;335(8686):376-378.PubMedGoogle ScholarCrossref
42.
Naegeli  O.  Naevi anaemici und Recklinghausensche Krankheit.  Arch Derm Syphilol. 1916;121:742-745.Google Scholar
43.
Schmidt  H.  Naevus anaemicus und Morbus Recklinghausen.  Dermat Ztschr. 1929;55:209-213.Google ScholarCrossref
44.
Hernandez-Martin  A, Baselga  E, Drolet  BA, Esterly  NB.  Juvenile xanthogranuloma.  J Am Acad Dermatol. 1997;36(3, pt 1):355-367.PubMedGoogle ScholarCrossref
45.
Sbidian  E, Hadj-Rabia  S, Riccardi  VM,  et al.  Clinical characteristics predicting internal neurofibromas in 357 children with neurofibromatosis-1: results from a cross-selectional study.  Orphanet J Rare Dis. 2012;7:62.PubMedGoogle ScholarCrossref
46.
Scott  RH, Mansour  S, Pritchard-Jones  K, Kumar  D, MacSweeney  F, Rahman  N.  Medulloblastoma, acute myelocytic leukemia and colonic carcinomas in a child with biallelic MSH6 mutations.  Nat Clin Pract Oncol. 2007;4(2):130-134.PubMedGoogle ScholarCrossref
47.
Ostergaard  JR, Sunde  L, Okkels  H.  Neurofibromatosis von Recklinghausen type I phenotype and early onset of cancers in siblings compound heterozygous for mutations in MSH6.  Am J Med Genet A. 2005;139A(2):96-105.PubMedGoogle ScholarCrossref
48.
Xu  A-E, Huang  B, Li  Y-W, Wang  P, Shen  H.  Clinical, histopathological and ultrastructural characteristics of naevus depigmentosus.  Clin Exp Dermatol. 2008;33(4):400-405.PubMedGoogle ScholarCrossref
Original Investigation
January 2014

Juvenile Xanthogranuloma and Nevus Anemicus in the Diagnosis of Neurofibromatosis Type 1

Author Affiliations
  • 1Dermatology, Centre Hospitalier Universitaire de Dijon
  • 2Medical Genetics, Centre Hospitalier Universitaire de Dijon
  • 3Research Unit EA 4271 Génétique des Anomalies du Développement, Université de Bourgogne, PRES Bourgogne-Franche Comté, France
  • 4Centre de Compétence Maladies Rares Neurofibromatose 1, Dijon, France
JAMA Dermatol. 2014;150(1):42-46. doi:10.1001/jamadermatol.2013.6434
Abstract

Importance  The diagnosis of neurofibromatosis type 1 (NF1) is based on 7 clinical criteria. However, they are of limited value before the age of 2 years. Juvenile xanthogranuloma (JXG) and nevus anemicus (NA) are commonly observed in children with NF1 and may be useful diagnostic clues.

Objectives  To evaluate the frequency of JXG and NA, to describe their clinical features, and to determine their diagnostic value in patients with NF1.

Design, Setting, and Participants  Retrospective medical record review of outpatients seen between January 1, 2005, and December 31, 2011. University hospital dermatology department affiliated with the French NF1 referral center network. Patients with NF1 diagnosed by at least 2 National Institutes of Health criteria and examined at our department.

Main Outcomes and Measures  Percentage of patients with NF1 who had JXG or NA categorized into 4 age groups.

Results  Among 72 patients with NF1 (median age, 15.4 years), 23 had JXG (10%) or NA (25%). Both lesions were more frequent (55%) in those younger than 2 years (JXG, 30%; NA, 35%). Most JXG lesions were multiple and resolved spontaneously. Cephalic and genital involvement was frequent. No patient with JXG developed chronic myelomonocytic leukemia. Nevus anemicus was present on the neck and upper chest in 72% of cases. Among 10 patients (14%) who had only 1 diagnostic criterion at first visit, including 9 younger than 2 years, JXG or NA was present in 8 (80%).

Conclusions and Relevance  We found a high frequency of JXG and NA in patients with NF1, especially in children younger than 2 years with fewer than 2 diagnostic criteria. Hence, JXG and NA appear helpful in improving early diagnosis of NF1 in young children and infants.

×